Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

Summary

CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC. The dose escalation phase of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part of the study using the optimal combination dose regimen.

Timeline

Start

2015-01-16

Primary completion

2016-12-21

Completion

2016-12-21

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment and business decision. No safety concerns were identified for the study drugs.”

Drugs

Indications